European friends, if you have an interest in learning more about AbSci's expression platform, SoluPro. Or would like to hear about AbSci's novel 12-week cell line optimization workflow, reach out to Kole Krieger to schedule a meeting. email@example.com
If you have an interest in learning more about AbSci's expression platform, SoluPro, or would like to hear about AbSci's novel 12-week cell line optimization workflow, reach out to Kole Krieger to schedule some time to meet. firstname.lastname@example.org
“Next-generation antibodies and proteins scaffolds present a roughly $14bn market opportunity by 2024 and getting to clinic six to 15 months sooner is a huge advantage, and a key driver, for partnering with AbSci.”
“This collaboration illustrates the need for new expression technologies that are capable of producing these next-generation antibody and protein scaffolds. We’ve shown SoluProTM can uniquely deliver on this industry need.”
“[SoluPro] enables “tuning” of protein production rates by optimizing for the best protein-folding and titer.”
“Sean McClain skipped the traditional academic route after graduating college…”
“It is rejuvenating to be working with a young and energetic company like AbSci. Their exciting technology not only has dramatic development, yield and production speed advantages for manufacture of complex biopharmaceuticals,” – Andrew J.S. Jones, D. Phil
AbSci to attend the Bio-Europe 2018 conference in Copenhagen, Denmark from 5th – 7th November 2018 If you would like to meet with an AbSci Business Development professional, please email us at partnering at abscibio.com
We’re excited to announce that AbSci made Seattle Business Magazine’s list of Washington’s 100 Best Companies to Work For! This year marks the 29th annual release of the Seattle Business Magazine’s 100 Best Companies to Work For list, as they look for the top...
AbSci Raises Oversubscribed $12M Series C to Fuel Commercialization of Its Groundbreaking Protein Expression Platform
The Series C Round led by Asahi Glass Co., Ltd. “AGC” includes participation from all prior investors (Phoenix Venture Partners, Oregon Venture Fund, WRF Capital, and Souther Co.) and new investors Columbia Ventures Corporation and GreenBridge.